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One Versus Two Stents
The Cause or the Effect?*
Antonio Colombo, MD, Alaide Chieffo, MD
Milan, Italy
It is now almost a decade that we have been discussing
optimal treatment of bifurcation lesions, and invariably we
come to the unanswered question: 1 or 2 stents?
Randomized clinical trials have been performed to assess
the optimal stenting strategy for bifurcation lesions (1,2),
and the answer is now clear: “if the lesion can be treated with
1 stent, there is no need to implant 2 stents (as intention-to-
treat), provided crossover is possible” (3).See page 255However, all of the randomized clinical trials evaluating
1- versus 2-stent strategies have been performed in non–left
main (LM) bifurcation lesions (1,2). Therefore, we still do
not have a clear answer on the optimal stenting strategy for
bifurcations involving the LM. For this reason, the COBIS
(Coronary Bifurcation Stenting Registry in South Korea)
Registry II (4) results published in this issue of JACC:
Cardiovascular Interventions are welcome. Before entering
into a more speciﬁc analysis, an important point needs to
be made: any registry, including COBIS, trying to compare
1 and 2 stents carries a major limitation due to the fact that
patients with LM bifurcation lesions requiring 2 stents have
a greater disease burden compared with patients who can
be treated with 1 stent. The disease burden for patients
requiring 2 stents can extend to other major epicardial ves-
sels. In summary, patients needing 2 stents at the distal LM
location have more atherosclerosis compared with patients
who can be treated with 1 stent. In addition, baseline clinical
and lesion characteristics of patients with bifurcation lesions
treated with 2 stents are more adverse compared with those
treated with 1 stent. Therefore, it is difﬁcult to attribute
worse clinical outcome to the stenting technique rather than
unfavorable baseline characteristics. This digression is
fundamental to critically evaluate the results of different*Editorials published in the JACC: Cardiovascular Interventions reﬂect the views of
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tation of observational registries compared with randomized
clinical trials.
Important and positive attributes of the COBIS registry
are the large number of consecutive patients with bifurcation
lesions (2,897 patients, 853 of whom had LM bifurcation
lesions), the multicenter design of the study, the exclusive
use of drug-eluting stents, and minimal exclusion criteria. As
expected, the 2-stent strategy was used more frequently in
LM lesions compared with other bifurcations (40.3% vs.
20.8%; p < 0.01).
It is important to highlight that patients needing 2 stents
were older; more frequently had a diagnosis of acute coro-
nary syndrome; had more multivessel disease, more true
bifurcations, and a higher SYNTAX score; more frequently
required treatment of additional lesions besides the bifur-
cation; and had a greater disease burden in the main and side
branch (more severe stenosis and longer lesions). Irrespective
of the strategy used to treat these 2 groups of patients, good
clinical judgment suggests that the prognosis of patients
treated with 2 stents is likely to be less favorable than
patients treated with 1 stent.
At a median follow-up of about 3 years, Song et al. (4)
observed the following:
1. In non-LM bifurcations, patients treated with 2 stents
had w3% to 4% (absolute) higher occurrence of
target lesion revascularization (TLR) and target ves-
sel revascularization (TVR) compared with patients
treated with 1 stent without any difference in hard
clinical events such as myocardial infarction and car-
diac death.
2. In LM bifurcations, patients treated with 2 stents had
more than double the occurrence of cardiac death,
myocardial infarction, TLR, and TVR compared with
patients treated with 1 stent.
3. The incidence of deﬁnite or probable stent thrombosis
was higher in patients treated with 2 stents. In non-
LM bifurcations, the difference did not reach statistical
signiﬁcance. Conversely, in LM bifurcations treated
with 2 stents, deﬁnite or probable stent thrombosis was
signiﬁcantly higher (3.2% vs. 0.6%; p < 0.01).
The provocative ﬁnding is that, after appropriate and
sophisticated statistical adjustment, the 2-stent strategy had
a hazard ratio of 2.38 (95% conﬁdence interval: 1.60 to 3.55;
p < 0.01) for the primary and secondary endpoints in
patients treated for LM bifurcation lesions.
How can we interpret these results? First, these results have
to be interpreted taking into account the important limita-
tions of this registry, as also pointed out by the authors.
There are remarkable differences in baseline clinical and
lesion characteristics between patients treated with 1 versus
2 stents, and the ability of statistical adjustment to correct
imbalances may be imperfect. Nevertheless, the hazard ratio
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265of 2.38 with an acceptable conﬁdence interval cannot be
dismissed.
Our belief is that we are dealing with 2 sets of variables:
patient/lesion complexity and higher metal burden (2 stents),
leading to a higher risk of thrombosis and associated major
adverse cardiovascular events such as death and myocardial
infarction. In addition, as pointed out in some randomized
studies and registries, the 2-stent strategy is technically more
complex and sometimes may be associated with a suboptimal
result (more frequently in unfavorable bifurcation angles),
leading to a higher risk of stent thrombosis.
Why does the 2-stent strategy affect only lesions located in
LM bifurcations? Our interpretation is that major adverse
cardiovascular events are rarely clinically silent in patients
treated with LM lesions, whereas lesions located in other
vessels, especially non–left anterior descending, may have
vascular complications without a manifest clinical event.
What clinical and technical message can we take from these
ﬁndings? First, because of the limitations of the study
design, we should be cautious in interpreting the results
before dismissing the 2-stent strategy. In addition, we
should consider the following points.
Every time we plan 2 stents in an LM bifurcation as
intention-to-treat, we need to take into account the option
of surgical revascularization, as correctly pointed out by the
authors. If the surgical option is not viable, we should
carefully evaluate the possibility of obtaining an optimal
acute result, such as adequate stent expansion and lumen
dimensions.
If we decide to proceed with 2 stents or we are crossing
over from a 1-stent strategy, an optimal technique is a must.
This includes lesion preparation, optimal stent expansion,
and assessment of the result by intravascular ultrasound
(5,6).
We need to accept that more metal means more foreign
body and a higher risk of an imperfect result. Intermediate
results should be evaluated with modern techniques such as
fractional ﬂow reserve (6), and crossover to 2 stents should
not be performed to please “coronary aesthetics.”
When we implant 2 stents, especially in an LM bifur-
cation, we should be more careful to optimize antiplatelettherapy, and when prescribing clopidogrel, it may be
important to evaluate platelet responsiveness (7) or to consider
using prasugrel or ticagrelor.
The bottom line is this: when we are treating patients with
more unfavorable baseline and lesion characteristics, espe-
cially if the target lesion is the LM bifurcation, more attention
must be paid, and any decision should be carefully weighed,
particularly when we need to implant 2 stents.
This study is telling us that 2 stents in LM bifurcations
might be an effect of greater disease burden, but might also
be the cause of more adverse clinical events.
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